| HBA1c > 7 (n 53) | HBA1c < 7 (n 47) | p value |
---|---|---|---|
Age (year) | 55 (49–61) | 54 (47–61) | 0.45 |
BSA (m2) | 2.04 ± 0.25 | 2.09 ± 0.25 | 0.40 |
BMI (kg/m2) | 33.95 ± 6.59 | 34.73 ± 8.42 | 0.63 |
Female sex (%) | 58.5 | 63,9 | 0.54 |
GFR c–c (ml/min) | 108.0 (81.4–144.2) | 117.7 (89.2–136.5) | 0.79 |
GFR MRDR (ml/min) | 75.9 (62.1–92.8) | 71.9 (64.3–83.7) | 0.23 |
Risk factors and CAD history (%) | |||
 Current smoker (%) | 13.2 | 4.2 | 0.16 |
 Hypertension (%) | 57.7 | 82.9 | <0.01 |
 Hyperlipidemia (%) | 75.0 | 82.9 | 0.33 |
 HDL (mg/dl) | 45.0 (37.0–54.5) | 45.5 (39.0–54.0) | 0.83 |
 Triglycerides (mg/dl) | 160.0 (98.0–230.0) | 118.5 (86.7–159.5) | <0.05 |
Inflammatory markers | |||
 Lpa (mg/dl) | 14.0 (7.0–35.0) | 13.0 (7.0–40.0) | 0.74 |
 hsCrP (mg/l) | 1.0 (0.4–4.0) | 1.0 (0.4–3.7) | 0.31 |
 Homocysteine (µmol/l) | 8.0 (6.0–9.0) | 8.0 (6.0–10.0) | 0.30 |
Coronary epicardial and microvascular function | |||
 CFR | 2.8 (2.3–3.6) | 2.8 (2.4–3.4) | 0.55 |
 CRF < 2.5 (%) | 39.6 | 29.8 | 0.53 |
 CBF%Ach | 27.4 (−16.6 to 67.4) | 15.2 (−28.2 to 69.1) | 0.79 |
 CBFAch < 50 % (%) | 62.2 | 61.7 | 1.00 |
 CLD%Ach | −10.0 (−24.8 to −3.4) | −12.5 (−31.8 to 0.0) | 0.93 |
 CLDAch < 20 % (%) | 28.3 | 36.1 | 0.52 |
 CBFbasal | 52.9 (33.5–70.4) | 51.2 (38.0–73.1) | 0.45 |
 LVEDP (mmHG) | 18.0 (12.2–24.7) | 17.0 (15.0–22.0) | 0.71 |
Diabetes status and treatment characterization | |||
 DM duration (months) | 60.0 (24.0–100.0) | 41.0 (8.0–90.0) | 0.22 |
 Fasting glucose (mg/dl) | 148.0 (118.0–179.0) | 125.0 (103.7–141.0) | <0.01 |
 Insulin (µIU/ml) | 14.0 (6.9–20.6) | 10.0 (5.1–18.0) | 0.47 |
 DM family history (%) | 60.4 | 47.7 | 0.29 |
 Insulin therapy (%) | 33.9 | 21.2 | 0.18 |
 Metformin (%) | 44.2 | 44.4 | 1.00 |
 Metformin only (%) | 28.8 | 35.5 | 0.66 |
 Insulin releasing (%) | 28.8 | 22.7 | 0.49 |
Medication (%) | |||
 BBlockers | 35.8 | 46.8 | 0.31 |
 CC blockers | 28.3 | 36.1 | 0.29 |
 Nitrates | 33.9 | 57.4 | <0.05 |
 ACE/ARB inhibitor | 30.1 | 38.3 | 0.53 |
 Lipid lowering | 40.1 | 70.2 | <0.05 |